Holen Sie sich die Stockscreener-App
363.39
0.06%
-0.23
Handel nachbörslich:
361.61
-1.78
-0.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$363.62
Offen:
$363.08
24-Stunden-Volumen:
1.63M
Relative Volume:
0.61
Marktkapitalisierung:
$196.12B
Einnahmen:
$37.30B
Nettoeinkommen (Verlust:
$7.80B
KGV:
25.27
EPS:
14.3793
Netto-Cashflow:
$8.60B
1W Leistung:
-2.88%
1M Leistung:
+7.60%
6M Leistung:
+11.44%
1J Leistung:
+20.98%
1-Tages-Spanne:
$361.14
$364.89
1-Wochen-Bereich:
$359.47
$375.25
52-Wochen-Spanne:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
363.39 | 196.25B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,188.58 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 623.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 441.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 308.90B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 295.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Hold |
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term growth narr - ad-hoc-news.de
Amgen stock reflects biotech heavyweight's steady role in US healthcare - ad-hoc-news.de
Munich Reinsurance Co Stock Corp in Munich Sells 2,916 Shares of Amgen Inc. $AMGN - MarketBeat
Ibex Wealth Advisors Increases Stake in Amgen Inc. $AMGN - MarketBeat
First Horizon Corp Boosts Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Regeneron Cites Medtronic Ruling In Amgen Bundling Case - Law360
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
How AI Is Changing Drug Discovery and What It Will Take to Unlock Its Full Potential - Amgen
Truist Raises its Price Target on Amgen (AMGN) - Insider Monkey
Amgen (AMGN): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Amgen stock responds to obesity drug progress and solid pipeline momentum - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Greenwood Capital Associates LLC Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen highlights its biotech pipeline as a driver for long-term growth - Ad-hoc-news.de
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370 - Moomoo
Amgen highlights oncology pipeline progress as a major biotech on Nasdaq - Ad-hoc-news.de
The Future of Genus Patenting Strategies for Antibodies Post- Amgen - IPWatchdog.com
Amgen Ecovation®: How Amgen Builds Sustainability Into Biotech - Amgen
Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar - Bloomberg Law News
Amgen extends its biotech footprint as a major U.S. pharma player - Ad-hoc-news.de
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? - The Motley Fool
Amgen Inc. $AMGN Holdings Cut by Swedbank AB - MarketBeat
Amgen Inc. focuses on biotechnology leadership as investors track long-term growth drivers - Ad-hoc-news.de
Amgen focuses on long-term growth as a leading biotech innovator - Ad-hoc-news.de
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims - Law360
How Safe Is Amgen's Dividend? - The Motley Fool
Amgen focuses on pipeline and strategy as investors watch earnings trajectory - AD HOC NEWS
Integrated Advisors Network LLC Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Kiley Juergens Wealth Management LLC Takes $1.25 Million Position in Amgen Inc. $AMGN - MarketBeat
Hodges Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc growth story and pipeline outlook - AD HOC NEWS
Amgen Inc. $AMGN Shares Sold by Burney Co. - MarketBeat
AMGN Maintained by Truist Securities -- Price Target Raised to $340 - GuruFocus
Amgen highlights its science-driven pipeline as investors weigh long-term growth - AD HOC NEWS
Amgen stock leans on its pipeline. Investors track a U.S. biotech giant. - AD HOC NEWS
Amgen highlights biotech strength as a large-cap innovator - AD HOC NEWS
Amgen’s Assembly and Packaging Facility, Ohio, US - Packaging Gateway
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
2026 Best Places to Work in Kentucky rankings announced - pmg-ky1.com
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Amgen Slides as Tavneos Scrutiny and Pipeline Questions Weigh on Shares - Quiver Quantitative
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $350 - GuruFocus
Nike, Amgen Share Losses Lead Dow's 238-Point Drop - Moomoo
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350 - Investing.com
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350 By Investing.com - Investing.com Canada
Amgen Inc. $AMGN Shares Bought by Stephens Inc. AR - MarketBeat
Amgen Inc. highlights its biotech scale as investors weigh long-term growth - AD HOC NEWS
Amgen Inc. (AMGN) Stock Analysis: Evaluating the 101% Return on Equity Amid a Diverse Portfolio - DirectorsTalk Interviews
Dividend Assets Capital LLC Sells 9,002 Shares of Amgen Inc. $AMGN - MarketBeat
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
3.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):